• 中国中文核心期刊
  • 中国科学引文数据库核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
高级检索

鸭乙型肝炎动物模型在药学领域的应用进展

汪纪楠, 施伟, 宋伟, 张亚琦, 张寅生, 徐宏江

汪纪楠, 施伟, 宋伟, 张亚琦, 张寅生, 徐宏江. 鸭乙型肝炎动物模型在药学领域的应用进展[J]. 中国药科大学学报, 2018, 49(6): 746-750. DOI: 10.11665/j.issn.1000-5048.20180617
引用本文: 汪纪楠, 施伟, 宋伟, 张亚琦, 张寅生, 徐宏江. 鸭乙型肝炎动物模型在药学领域的应用进展[J]. 中国药科大学学报, 2018, 49(6): 746-750. DOI: 10.11665/j.issn.1000-5048.20180617
shu
WANG Jinan, SHI Wei, SONG Wei, ZHANG Yaqi, ZHANG Yinsheng, XU Hongjiang. Advances in the application of duck hepatitis B animal model in pharmaceutical field[J]. Journal of China Pharmaceutical University, 2018, 49(6): 746-750. DOI: 10.11665/j.issn.1000-5048.20180617
Citation: WANG Jinan, SHI Wei, SONG Wei, ZHANG Yaqi, ZHANG Yinsheng, XU Hongjiang. Advances in the application of duck hepatitis B animal model in pharmaceutical field[J]. Journal of China Pharmaceutical University, 2018, 49(6): 746-750. DOI: 10.11665/j.issn.1000-5048.20180617
shu

鸭乙型肝炎动物模型在药学领域的应用进展

  • 江苏省抗病毒靶向药物研究重点实验室，正大天晴药业集团股份有限公司研究院

基金项目: 江苏省抗病毒靶向药物研究重点实验室资助项目(No.SBM2016200031)；江苏省“六大人才高峰”高层次人才培养项目(No.2016-SWYY-199)

Advances in the application of duck hepatitis B animal model in pharmaceutical field

摘要

    摘要
  • 摘要: 鸭乙型肝炎病毒的基因组、复制方式和发病机制与人乙型肝炎病毒相似，且鸭乙肝病毒的天然宿主容易获得、价格低廉、感染成功率高，因此鸭乙型肝炎动物模型已被广泛应用于药物筛选、药理学和病理学研究。在应用于药物筛选时，该模型容易获得，感染成功率高且具有良好的稳定性。在药理学研究中，该模型能够持续维持高水平的病毒DNA复制，并且能够出现明显的肝脏损伤表型，可以反映不同机制药物的药理药效作用。而在病理机制研究中，该模型则具有完整的病毒生命周期，且在感染动物肝脏细胞中可检测到cccDNA，可以帮助科研人员更好的研究人乙型肝炎病毒致病机制。本文对鸭乙型肝炎动物模型在药物筛选、药理和病理研究中的应用进行综述，并对其应用前景进行展望。
    Abstract: The genome, replication mode and nosogenesis of duck hepatitis B virus are similar to those of human hepatitis B virus. In addition, the natural host of duck hepatitis B virus is readily available, cheap and has a high success rate of infection. Therefore, duck hepatitis B virus-infected models have been widely used for drug screening, pharmacological and pathological studies. For drug screening, the model is easy to obtain with high infection success rate and good stability. In the pharmacological research, the model can maintain high levels of viral DNA replication in the hepatocytes and exhibit significant damaged liver phenotypes which can reflect the pharmacological effects of drugs with different mechanisms. Also in the pathologic mechanisms research, the model has entire virus life cycle and maintains a pool of covalent closed-loop DNA in the hepatocytes, which can help scientific researchers better understand human hepatitis B virus. This article reviews the applications of duck hepatitis B animal model in drug screening, pharmacological and pathological studies, also outlooks the application prospect of this model.
    • HTML全文
    • 参考文献(22)
  • [1] Dandri M,Lütgehetmann M,Petersen J.Experimental models and therapeutic approaches for HBV[C].//Semin Immunopathol,Springer-Verlag,2013,35(1):7-21.
    [2] Thomas E,Liang TJ.Experimental models of hepatitis B and C-new insights and progress[J].Nat Rev Gastroenterol Hepatol,2016,13(6):362-374.
    [3] Guo WN,Bin Zhu L A,Yang DL,et al.Animal models for the study of hepatitis B virus infection[J].Zool Res,2018,39(1):25-31.
    [4] Tang H,Griffin J,Innaimo S,et al.The discovery and development of a potent antiviral drug,entecavir,for the treatment of chronic hepatitis B[J].J Clin Transl Hepatol,2013,1(1):51-58.
    [5] Genovesi EV,Lamb L,Medina I,et al.Efficacy of the carbocyclic 2′-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection[J].Antimicrob Agents Chemother,1998,42(12):3209-3217.
    [6] Marion PL, Salazar FH, Winters MA, et al. Potent efficacy of entecavir(BMS-200475)in a duck model of hepatitis B virus replication[J].Antimicrob Agents Chemother,2002,46(1):82-88.
    [7] Foster WK,Miller DS,Marion PL,et al.Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection[J].Antimicrob Agents Chemother,2003,47(8):2624-2635.
    [8] Tian X,Li Z,Liu M.Inhibitory effect of BP0018 on hepatitis B virus in vivo[J] Chin J New Drug(中国新药杂志),2016,25(11):1293-1297.
    [9] Quinet J, Jamard C, Vaillant A, et al. Achievement of surface antigen clearance in the liver by combination therapy with REP 2139-Ca and nucleoside analogues against chronic hepatitis B[C]//International Liver Congress.2016:12-17.
    [10] Le Guerhier F,Thermet A,Guerret S,et al.Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model[J].J Hepatol,2003,38(3):328-334.
    [11] Brikh C,Jamard C,Quinet J,et al.Therapeutic effect against hepatitis B of various nucleic acid polymers in the chronic DHBV infection model[J].J Hepatol,2015,62:S518-S518.
    [12] Quinet J,Jamard C,Burtin M,et al.Nucleic acid polymer REP 2139 and nucleos(T)ide analogues act synergistically against chronic hepadnaviral infection in vivo in Pekin ducks[J].Hepatology,2018,67(6):2127-2140.
    [13] Cai D,Mills C,Yu W,et al.Identification of the disubstituted?敳瑵?慦汯??業???洠浣畯湭潰杯敵湮楤捳椠瑡祳?慳湰摥?灩牦潩瑣攠捩瑮楨癩敢?整景晲楳挠慯捦礠?潥晰????噩??乂??癩慲捵捳椠湣敯獶?敬硥灮牴敬獹猠楣湬杯?敥湤瘠散汩潲灣敵?慡湲搠?捎慁瀠獦楯摲?晡畴獩楯潮湛?灝爮漼瑩放楁湮獴?業湩?摲畯换欠獁?摥敮汴楳瘠敃牨敥摭?扴票?慲琼琯敩渾甬愲琰攱搲??楢?匵愶氼洯潢渾攨氱永愩?琴礲瀷样椭洴甲爸椸甮洼??椯?孛?崴??椠????湡瑧敮条爠??本牌楩捵??椬????????戾?????戼?????????????benzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids[J].J Virol,2013,87(12):6931-6932.
    [14] Liu Y,Peng Y,Lu J,et al.Design,synthesis,and biological evaluation of new 1,2,3-triazolo-2′-deoxy-2′-fluoro-4′-azido nucleoside derivatives as potent anti-HBV agents[J].Eur J Med Chem,2018,143:137-149.
    [15] Tohidi-Esfahani R,Vickery K,Cossart Y.The early host innate immune response to duck hepatitis B virus infection[J].J Gen Virol,2010,91(2):509-520.
    [16] Hao YH,Li AY,Ding HH,et al.Experimental study on duck hepatitis B virus infection model by different kinds of ducklings and anti-viral effect[J].Chin J Comp Med(中国比较医学杂志),2012,22(11):23-26.
    [17] Reaiche GY,Le Mire MF,Mason WS,et al.The persistence in the liver of residual duck hepatitis B virus covalently closed circular DNA is not dependent upon new viral DNA synthesis[J].Virology,2010,406(2):286-292.
    [18] Saade F,Buronfosse T,Guerret S,et al.In vivo infectivity of liver extracts after resolution of hepadnaviral infection following therapy associating DNA vaccine and cytokine genes[J].J Viral Hepatitis,2013,20(4):e56-e65.
    [19] Koumbi L, Karayiannis P. The epigenetic control of hepatitis B virus modulates the outcome of infection[J].Front Microbiol,2016,6:1491.
    [20] Liu F,Campagna M,Qi Y,et al.Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes[J].PLoS Pathog,2013,9(9):e1003613.
    [21] Zheng Q,Bai L,Zheng S,et al.Efficient inhibition of duck hepatitis B virus DNA by the CRISPR/Cas9 system[J].Mol Med Rep,2017,16(5):7199-7204.
    [22] Liu S,Jia R,Li Q,
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  566
  • HTML全文浏览量:  17
  • PDF下载量:  1488
  • 被引次数: 0
出版历程
  • 刊出日期:  2018-12-24

目录

摘要
HTML全文
    参考文献(22)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    版权所有：《中国药科大学学报》编辑部苏ICP备05007142号

    地址：江苏省南京市鼓楼区童家巷24号（210009）电话: 025-83271566E-mail: xuebao@cpu.edu.cn

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计

    访问量：304009

    x 关闭 永久关闭